Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 21 August 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Pharmaids Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a notable shift from its previously positive growth trajectory. Despite some operational strengths, the company faces challenges in liquidity and profitability, reflected in its recent downgrade to a Strong Sell rating by MarketsMOJO.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 10 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 27 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 03 June 2026, providing investors with the latest insights into its performance and outlook.

A sharp decline of 15.62% in intraday trading dragged Pharmaids Pharmaceuticals Ltd to a fresh 52-week low of Rs 25.6 on 1 Jun 2026, extending its downward trajectory amid persistent selling pressure.

Pharmaids Pharmaceuticals Ltd., a Hyderabad-based contract research and manufacturing services company, reported its Q4 FY26 results that reveal a troubling paradox: robust revenue growth coupled with deteriorating profitability. The micro-cap pharmaceutical firm posted a consolidated net loss of ₹1.81 crores for the March 2026 quarter, marking a 27.02% sequential decline and a 54.06% year-on-year deterioration, even as net sales surged 50.52% YoY to ₹7.18 crores.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 18 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.